Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.

Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Polenta B, Spinello M, Boscaro M, Arnaldi G

Pituitary1 Feb 2015Cited by 15 (Europe PMC)

PMID24482099DOI10.1007/s11102-014-0557-xPepBankPUB-24482099

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In Cushing's disease patients receiving pasireotide, LNSC decreased in six patients at day 15.
In plain wordsIn Cushing's disease patients receiving pasireotide, saliva cortisol decreased in six patients at day 15.
Peptide
Pasireotide
Outcome
DecreaseLNSC responders at day 15
Study
n = 7
Outcome group
Cortisol Control · Endocrine and hormones
Studied dose
600 μg twice daily · subcutaneous · 15 daysAs given in this study (human).
Measurements
Patients with reduced LNSC
6 patients
day 15; of 7
Source sentences
Summary
At day 15, LNSC was reduced in six patients.
3 context sentences(design, population, supporting numbers)
Summary · context
Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis.
Summary · context
Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days.
Summary · context
LNSC and UFC levels were assessed at baseline and day 15.
Report a problemFND-2448209901
02HumanNon-randomized trialEfficacy outcome
In Cushing's disease patients receiving pasireotide, LNSC decreased by 20% from baseline on day 1.
In plain wordsIn Cushing's disease patients receiving pasireotide, saliva cortisol decreased by 20% on day 1.
Peptide
Pasireotide
Outcome
DecreaseLNSC change at day 1
Study
n = 7
Outcome group
Cortisol Control · Endocrine and hormones
Studied dose
600 μg twice daily · subcutaneousAs given in this study (human).
Measurements
LNSC change from baseline
−20%
day 1
Source sentences
Summary
LNSC decreases were observed from day 1 (-20%) and persisted until day 15 (overall mean reduction from baseline -51%), with the greatest decrease on day 5 (-58%).
3 context sentences(design, population, supporting numbers)
Summary · context
Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis.
Summary · context
Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days.
Summary · context
LNSC and UFC levels were assessed at baseline and day 15.
Report a problemFND-2448209902
03HumanNon-randomized trialEfficacy outcome
In Cushing's disease patients receiving pasireotide, mean LNSC decreased by 51% from baseline at day 15.
In plain wordsIn Cushing's disease patients receiving pasireotide, mean saliva cortisol decreased by 51% at day 15.
Peptide
Pasireotide
Outcome
DecreaseLNSC change at day 15
Study
n = 7
Outcome group
Cortisol Control · Endocrine and hormones
Studied dose
600 μg twice daily · subcutaneous · 15 daysAs given in this study (human).
Measurements
Mean LNSC reduction from baseline
−51%
day 15
Source sentences
Summary
LNSC decreases were observed from day 1 (-20%) and persisted until day 15 (overall mean reduction from baseline -51%), with the greatest decrease on day 5 (-58%).
3 context sentences(design, population, supporting numbers)
Summary · context
Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis.
Summary · context
Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days.
Summary · context
LNSC and UFC levels were assessed at baseline and day 15.
Report a problemFND-2448209903
04HumanNon-randomized trialEfficacy outcome
In Cushing's disease patients receiving pasireotide, the greatest LNSC decrease occurred on day 5, at 58% below baseline.
In plain wordsIn Cushing's disease patients receiving pasireotide, saliva cortisol decreased most on day 5, by 58%.
Peptide
Pasireotide
Outcome
DecreaseLNSC change at day 5
Study
n = 7
Outcome group
Cortisol Control · Endocrine and hormones
Studied dose
600 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Greatest LNSC decrease from baseline
−58%
day 5
Source sentences
Summary
LNSC decreases were observed from day 1 (-20%) and persisted until day 15 (overall mean reduction from baseline -51%), with the greatest decrease on day 5 (-58%).
3 context sentences(design, population, supporting numbers)
Summary · context
Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis.
Summary · context
Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days.
Summary · context
LNSC and UFC levels were assessed at baseline and day 15.
Report a problemFND-2448209904
05HumanNon-randomized trialEfficacy outcome
In Cushing's disease patients receiving pasireotide, UFC decreased in all patients at day 15.
In plain wordsIn Cushing's disease patients receiving pasireotide, urinary cortisol decreased in all patients at day 15.
Peptide
Pasireotide
Outcome
DecreaseUFC decrease at day 15
Study
n = 7
Outcome group
Cortisol Control · Endocrine and hormones
Studied dose
600 μg twice daily · subcutaneous · 15 daysAs given in this study (human).
Source sentences
Summary
At day 15, UFC levels were decreased in all patients and normalized in one that restored also salivary cortisol rhythm.
3 context sentences(design, population, supporting numbers)
Summary · context
Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis.
Summary · context
Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days.
Summary · context
LNSC and UFC levels were assessed at baseline and day 15.
Report a problemFND-2448209905
06HumanNon-randomized trialEfficacy outcome
In Cushing's disease patients receiving pasireotide, UFC normalized in one patient at day 15.
In plain wordsIn Cushing's disease patients receiving pasireotide, urinary cortisol normalized in one patient at day 15.
Peptide
Pasireotide
Outcome
Not applicableUFC normalization at day 15
Study
n = 7
Outcome group
Cortisol Control · Endocrine and hormones
Studied dose
600 μg twice daily · subcutaneous · 15 daysAs given in this study (human).
Measurements
Patients with normalized UFC
1 patients
day 15; of 7
Source sentences
Summary
At day 15, UFC levels were decreased in all patients and normalized in one that restored also salivary cortisol rhythm.
3 context sentences(design, population, supporting numbers)
Summary · context
Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis.
Summary · context
Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days.
Summary · context
LNSC and UFC levels were assessed at baseline and day 15.
Report a problemFND-2448209906
07HumanNon-randomized trialEfficacy outcome
In Cushing's disease patients receiving pasireotide, the patient with normalized UFC also restored salivary cortisol rhythm at day 15.
In plain wordsIn Cushing's disease patients receiving pasireotide, the patient with normal urinary cortisol also regained salivary cortisol rhythm at day 15.
Peptide
Pasireotide
Outcome
Not applicableRestoration of salivary cortisol rhythm
Study
n = 7
Outcome group
Cortisol Control · Endocrine and hormones
Studied dose
600 μg twice daily · subcutaneous · 15 daysAs given in this study (human).
Measurements
Patients with restored salivary cortisol rhythm
1 patients
day 15; of 7; same patient with normalized UFC
Source sentences
Summary
At day 15, UFC levels were decreased in all patients and normalized in one that restored also salivary cortisol rhythm.
3 context sentences(design, population, supporting numbers)
Summary · context
Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis.
Summary · context
Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days.
Summary · context
LNSC and UFC levels were assessed at baseline and day 15.
Report a problemFND-2448209907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.